- Bill / Initiative
- AB 113
- Institution / Partner
- CIAPM (California Initiative to Advance Precision Medicine)
- Population Served
- Veterans
- Funding
- $4.7M
$175M+
Public Funding Influenced
18
States With VETS-Driven Policy
29
Policy Records Tracked
Where We Work
U.S. Policy Impact Map
Explore where VETS has led, supported, or influenced legislation, funding, research programs, and access infrastructure across the country. Select a highlighted state to filter the policy portfolio below.
Click a highlighted state to view its policy records.
Explore the Policy Portfolio
Search and filter VETS' policy records by state, year, role, status, and research focus. Select any record to view full details.
- Bill / Initiative
- Executive Order
- Institution / Partner
- Federal agencies / ARPA-H
- Population Served
- Patients with serious mental illness; future PAT patients
- ARPA-H Eligibility
- Supports qualifying state research programs
Program Notes
Built on the state-level policy infrastructure VETS helped establish, especially Texas HB 1802, Texas SB 2308, and related state programs.
- Bill / Initiative
- Budget Appropriation
- Institution / Partner
- Emory University
- Principal Investigator / Lead
- Dr. Barbara Rothbaum
- Population Served
- Veterans with PTSD
- Funding
- $1M
Program Notes
Builds directly on the 2025 Georgia appropriation and the Douglas Mike Day Act funding.
- Bill / Initiative
- HB 3834
- Population Served
- Veterans and civilians with PTSD, TBI, and substance use disorders
- Funding
- No current appropriation
- ARPA-H Eligibility
- Yes
Program Notes
Appropriation effort planned for 2027. Companion to Texas SB 2308. Part of consortium with Texas, West Virginia, Missouri, Tennessee, and Mississippi.
- Bill / Initiative
- HB 390
- Institution / Partner
- University of Utah / Huntsman Mental Health Institute
- Population Served
- Veterans with PTSD
- Funding
- $1M + up to $2M philanthropic match
- ARPA-H Eligibility
- Yes
Program Notes
HMHI has elected to pursue 5-MeO-DMT research. Matching philanthropic funds of up to $2M to be awarded by HMHI donors.
- Bill / Initiative
- HB 26-1325
- Institution / Partner
- Up to 5 research/treatment sites
- Population Served
- Veterans and civilians within Natural Medicine program framework
- Funding
- No state appropriation
- ARPA-H Eligibility
- Yes
Program Notes
Funding contingent on gifts, grants, and donations. Allows up to five sites to establish research and treatment programs.
- Bill / Initiative
- SB 77
- Population Served
- Veterans with PTSD, TBI, and substance use disorders
- Funding
- No state appropriation
- ARPA-H Eligibility
- Yes
Program Notes
Part of the growing multi-state ibogaine research consortium catalyzed by SB 2308.
- Bill / Initiative
- SB 43
- Population Served
- Veterans with PTSD, TBI, and substance use disorders; broader population for psilocybin
- Funding
- No state appropriation
- ARPA-H Eligibility
- Yes
Program Notes
Includes a veteran-focused ibogaine/PAT pilot and a separate psilocybin research pilot. Influenced by Texas SB 2308 and HB 1802.
- Bill / Initiative
- HB 314
- Population Served
- Individuals with opioid use disorder, substance use disorders, and certain mental health conditions
- Funding
- $5M
- ARPA-H Eligibility
- Yes
Program Notes
Requires institutions to pursue FDA approval, provide matching funds, and report progress and safety outcomes. Influenced by Texas SB 2308.
- Bill / Initiative
- SB 2149
- Population Served
- Veterans with PTSD, TBI, and substance use disorders
- Funding
- No state appropriation
- ARPA-H Eligibility
- Yes
Program Notes
Part of the growing multi-state ibogaine research consortium catalyzed by SB 2308.
- Bill / Initiative
- AB 1103
- Institution / Partner
- California research institutions
- Population Served
- Researchers and future patients across California
Program Notes
Explore This Victory ›Builds on AB 2841. Establishes expedited review process and extends open-meeting exemptions for researchers.
- Bill / Initiative
- Budget Appropriation
- Institution / Partner
- Emory University
- Principal Investigator / Lead
- Dr. Barbara Rothbaum
- Population Served
- Veterans with PTSD
- Funding
- $1M
- ARPA-H Eligibility
- Yes
Program Notes
First Georgia veteran dosed with state-funded MDMA in March 2026. Builds from the Douglas Mike Day Act trial.
- Bill / Initiative
- S 2283
- Institution / Partner
- To be announced
- Population Served
- New Jersey patients; populations TBD by grantees
- Funding
- $6M
- ARPA-H Eligibility
- Yes
Program Notes
Explore This Victory ›Three $2M grants to in-state hospital systems. Institutions to be publicly announced upon contract execution.
- Bill / Initiative
- SB 2308
- Institution / Partner
- UT Health Houston leading multi-institution consortium
- Population Served
- Veterans and civilians with PTSD, TBI, substance use disorders, and co-occurring conditions
- Funding
- $100M
Program Notes
Explore This Victory ›Initial $50M appropriation increased to $100M in 2026. First public funding for ibogaine research anywhere in the world. Influenced companion legislation in 12+ states, with 7 passed into law.
- Bill / Initiative
- HB 2871
- Institution / Partner
- To be determined through RFP
- Population Served
- Veterans and civilians; institutions TBD through RFP
- Funding
- $10M
- ARPA-H Eligibility
- Yes
Program Notes
Two $5M grants. RFP underway; no institutions publicly announced. Builds on Arizona SB 1726 from 2023.
- Bill / Initiative
- HB 3322
- Institution / Partner
- Illinois regulatory system
- Population Served
- Future patients receiving FDA-approved psychedelic therapies
Program Notes
Aligns Illinois regulatory decisions with FDA approval and DEA rescheduling to support immediate access upon federal approval.
- Bill / Initiative
- HB 2218
- Institution / Partner
- Kansas regulatory system
- Population Served
- Future patients
Program Notes
Allows prescribing, dispensing, and use upon FDA approval and DEA rescheduling.
- Bill / Initiative
- SB 2056
- Institution / Partner
- Mississippi regulatory system
- Population Served
- Future patients
Program Notes
Allows prescribing, dispensing, and use of crystalline polymorph psilocybin upon FDA approval and DEA rescheduling.
- Bill / Initiative
- HB 1099
- Institution / Partner
- South Dakota regulatory system
- Population Served
- Future patients
Program Notes
Allows prescribing, dispensing, and use of crystalline polymorph psilocybin upon FDA approval and DEA rescheduling.
- Bill / Initiative
- SB 379 / HB 1347
- Institution / Partner
- Virginia regulatory system
- Population Served
- Future patients
Program Notes
Allows prescribing, dispensing, and use of crystalline polymorph psilocybin upon FDA approval and DEA rescheduling.
- Bill / Initiative
- AB 2841
- Institution / Partner
- Research Advisory Panel of California
- Population Served
- Researchers, institutions, and future patients
Program Notes
Authorized RAPC closed-session meetings to review sensitive research, protecting IP and trade secrets. Established a precedent for procedural reform beyond appropriations.
- Bill / Initiative
- HB 548
- Institution / Partner
- State task force
- Population Served
- Maryland residents; all potential patient populations
Program Notes
Directed to make recommendations to the Governor and Legislature. Influenced by Texas HB 1802.
- Bill / Initiative
- SB 266
- Institution / Partner
- Intermountain Health
- Population Served
- Utah behavioral health patients
Program Notes
Expanded the HB 167 task force framework into direct treatment authorization. Influenced by Texas HB 1802 and Utah HB 167.
- Bill / Initiative
- H.R. 3684
- Institution / Partner
- UT Health San Antonio, Emory University, Walter Reed National Military Medical Center
- Principal Investigator / Lead
- Dr. Alan Peterson; Maj. Aaron Wolfgang
- Population Served
- Active duty military, National Guard, Reserve personnel, and active duty service members with PTSD
- Funding
- $10M
Program Notes
Explore This Victory ›Authorized two $5M grants: one to UT Health San Antonio & Emory University, and one to Walter Reed. Includes MDMA + Prolonged Exposure Therapy trial and active-duty clinical research.
- Bill / Initiative
- SB 1726
- Institution / Partner
- Alira Health & Scottsdale Research Institute
- Principal Investigator / Lead
- Dr. Sue Sisley
- Population Served
- Veterans, firefighters, and law enforcement officers
- Funding
- $5M
Program Notes
Funded Phase 1, 2, and 3 clinical trials for PTSD, depression, and anxiety. Created Arizona's Psilocybin Research Advisory Council as a permanent body.
- Bill / Initiative
- SB 242
- Institution / Partner
- Psychedelic Medicines Working Group
- Population Served
- Nevada residents; all potential patient populations
Program Notes
Working group published a report creating a framework for expanded access and research in Nevada.
- Bill / Initiative
- HB 1
- Population Served
- Veterans with PTSD
- Funding
- $6M
Program Notes
Contracting was delayed; funds were reappropriated in FY2026 and contracting is now underway.
- Bill / Initiative
- HB 167
- Institution / Partner
- State task force
- Population Served
- Utah residents; governmental, medical, and patient stakeholders
Program Notes
Recommendations paved the way for expanded FDA clinical research in Utah and later implementation efforts, including Utah SB 266 and HB 390.
- Bill / Initiative
- HB 1802
- Institution / Partner
- Baylor College of Medicine & Menninger Clinic; Texas Health and Human Services Commission
- Principal Investigator / Lead
- Dr. Lynnette Averill, PhD
- Population Served
- Veterans only
- Funding
- $2.2M
Program Notes
Explore This Victory ›First Texas veteran dosed with state-funded psilocybin in January 2026; expected conclusion Q4 2026. Cited as a model in Nevada, Utah, Arizona, Illinois, Maryland, and beyond. Helped catalyze the McGill Center at UT Austin Dell Medical School.
No policy records match those filters yet. to see the full portfolio.
Clarity & Transparency
Policy Glossary
Key terms used throughout this dashboard, defined for clarity and transparency.
- 5-MeO-DMT
- A potent, naturally occurring psychedelic compound being explored for treatment-resistant depression and anxiety.
- ARPA-H
- The Advanced Research Projects Agency for Health, a federal agency funding high-risk, high-reward health research.
- Clinical Trial
- A structured research study evaluating the safety and efficacy of a medical treatment in human participants.
- FDA-Model Policy
- State legislation that funds psychedelic research within the existing FDA clinical trial framework rather than bypassing federal regulation.
- Ibogaine
- A naturally occurring psychoactive compound being researched for its potential to treat traumatic brain injury and substance use disorders.
- MDMA
- A synthetic compound in advanced clinical trials for PTSD treatment when combined with psychotherapy.
- Psilocybin
- A naturally occurring psychedelic compound found in certain mushrooms, currently in clinical trials for depression and PTSD.
- Psychedelic-Assisted Therapy
- A clinical approach combining a psychedelic substance with professional psychotherapy in a controlled medical setting.
- RFP
- Request for Proposals — a formal solicitation inviting qualified institutions to submit bids for funded research or services.
- Right to Try
- Federal and state laws allowing terminally ill patients to access investigational treatments that have completed Phase I clinical trials.
- Schedule I
- The most restrictive DEA drug classification, indicating high abuse potential and no currently accepted medical use.
- Schedule II
- A DEA drug classification for substances with high abuse potential but recognized medical use under severe restrictions.
- State Appropriation
- Legislative allocation of state funds for a specific purpose, such as research or program development.
- Trigger Law
- State legislation designed to automatically authorize therapeutic access once federal agencies approve or reschedule a psychedelic compound.
Help Us Expand Access to
Psychedelic Research for Veterans
Your support fuels the advocacy, research, and coalition building that makes these policy victories possible.
